Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
adult, Research, clinical trials, MPN, Combination therapy, Clinical Research, Chronic Myeloid Malignancies, Diseases, patient-reported outcomes, Therapies, Adverse Events, Myeloid Malignancies, Study Population, Human
Type: Oral
Hematology Disease Topics & Pathways:
adult, Research, clinical trials, MPN, Combination therapy, Clinical Research, Chronic Myeloid Malignancies, Diseases, patient-reported outcomes, Therapies, Adverse Events, Myeloid Malignancies, Study Population, Human
Sunday, December 10, 2023: 4:30 PM-6:00 PM
Ballroom 20CD
(San Diego Convention Center)
Moderators:
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center
and
Shireen Sirhan, MD, FRCP, Jewish General Hospital
Disclosures:
Bose: Incyte, BMS, CTI, Morphosys, Blueprint, Cogent, Sumitomo, Ionis: Honoraria, Research Funding; Kartos, Telios, Disc, Janssen, Geron: Research Funding; GSK, Novartis, Karyopharm, AbbVie, Pharma Essentia, Jubilant, Morphic: Honoraria. Sirhan: Novartis: Honoraria, Research Funding; GSK: Honoraria.
Session: In this session, we turn our attention to ruxolitinib and its synergistic potential in the treatment of myeloproliferative neoplasms (MPN). The primary focus will be on the use of ruxolitinib in polycythemia vera and emerging combinations of ruxolitinib with other therapeutic agents in myelofibrosis. By highlighting the latest research abstracts, this session is poised to stimulate rich discussions on the advantages, challenges, and nuances of these combination therapies. Whether you're deeply embedded in hematology research or are venturing into the MPN arena, this session promises a deep dive into the innovative realm of ruxolitinib combinations, hinting at the next frontier in MPN management.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH